CT Perfusion in the Evaluation of Effects of Lipo-PGE1 on Non-cancerous Liver Tissues Before and After TACE in Hepatocellular Carcinoma Patients

Objective To investigate the effects of lipo-PGE1 on non-cancerous liver tissues in hepatocellular carcinoma (HCC) patients before and after TACE using CT perfusion. Materials and Methods Forty six HCC patients were divided into the control group and the study group randomly. Perfusion parameters of two groups were compared using CT perfusion. Results In the study group, hepatic arterial perfusion (HAP), portal venous perfusion (PVP), total liver perfusion (TLP) before TACE was (0.18±0.13) ml·min-1·ml-1, (1.64 ±0.44) ml·min-1·ml-1, (1.82±0.32) ml·min-1·ml-1, individually. In the control group, HAP, PVP, TLP before TACE was (0.16±0.17) ml·min-1·ml-1, (1.41 ±0.37) ml·min-1·ml-1, (1.57±0.28) ml·min-1·ml-1, respectively. There was significant difference in PVP (P=0.00) and TLP (P=0.01) between two groups, and there was no significant difference in HAP (P0.05) between two groups. In the control group, HAP, PVP, TLP one month after TACE was (0.09±0.07) ml·min-1·ml-1, (1.35±0.27 )ml·min-1·ml-1, ( 1.44±0.18) ml·min-1·ml-1, individually. HAP and TLP significantly decreased (P0.05). In the study group, HAP, PVP, TLP one month after TACE was (0.19±0.11) ml·min-1·ml-1, (1.71±0.34) ml·min-1·ml-1,( 1.90±0.33) ml·min-1·ml-1, individually. There was no significant difference between HAP, PVP, TLP before TACE and one month after TACE (P0.05). Conclusion CT hepatic perfusion can quantitatively assess hemodynamic changes of non-cancerous liver tissues in HCC patients before and after TACE. Lipo PGE1 might increase hepatic perfusion and improve liver function.